Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Racemetyrosine - Syros Pharmaceuticals

Next Previous
Drug Profile

Racemetyrosine - Syros Pharmaceuticals

Alternative Names: a-methylparatyrosine; Alpha metyrosine; D/L-alpha metyrosine; SM-88; SM-88i; SM-88n

Latest Information Update: 11 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tyme Technologies
  • Developer Georgetown University; Pancreatic Cancer Action Network; Syros Pharmaceuticals; The Joseph Ahmed Foundation
  • Class Amino acids; Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Immunomodulators; Protein synthesis inhibitors; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Ewing's sarcoma; Prostate cancer
  • Preclinical Cancer
  • No development reported Glioma; Osteosarcoma
  • Discontinued Pancreatic cancer

Most Recent Events

  • 18 Jan 2024 Efficacy and adverse events data from a phase III Precision Promise (PrP) Bayesian platform trial in Pancreatic cancer presented at the Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
  • 10 Feb 2023 Tyme terminates phase II trial in Breast Cancer in the US (PO, Capsule) (NCT04720664)
  • 16 Sep 2022 Syros Pharmaceuticals acquires Racemetyrosine from Tyme Technologies

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top